Tamsulosin + Solifenacin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Lower Urinary Tract Symptoms
Conditions
Lower Urinary Tract Symptoms
Trial Timeline
Oct 1, 2011 → Jul 1, 2014
NCT ID
NCT01457573About Tamsulosin + Solifenacin
Tamsulosin + Solifenacin is a approved stage product being developed by Astellas Pharma for Lower Urinary Tract Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT01457573. Target conditions include Lower Urinary Tract Symptoms.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01457573 | Approved | Completed |
| NCT02715024 | Approved | Completed |
Competing Products
20 competing products in Lower Urinary Tract Symptoms